Intellia Therapeutics (NASDAQ:NTLA) Given Buy Rating at HC Wainwright

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report)'s stock had its "buy" rating restated by HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They presently have a $30.00 price objective on the stock. HC Wainwright's price objective suggests a potential upside of 329.18% from the stock's current price.

NTLA has been the subject of several other reports. Guggenheim decreased their price target on shares of Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating for the company in a report on Monday, May 12th. Wall Street Zen raised shares of Intellia Therapeutics to a "sell" rating in a report on Monday, March 3rd. JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $13.00 price target (down from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. Truist Financial cut their price objective on shares of Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Finally, Citigroup cut their price objective on shares of Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $36.75.

Intellia Therapeutics Trading Down 6.2%

NTLA stock traded down $0.46 during mid-day trading on Thursday, hitting $6.99. 8,839,884 shares of the company were exchanged, compared to its average volume of 2,689,845. The company has a market capitalization of $724.05 million, a PE ratio of -1.28 and a beta of 2.33. Intellia Therapeutics has a twelve month low of $5.90 and a twelve month high of $28.18. The firm has a fifty day simple moving average of $7.97 and a 200 day simple moving average of $10.37.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, topping the consensus estimate of ($1.26) by $0.16. The company had revenue of $16.63 million for the quarter, compared to analyst estimates of $11.39 million. Intellia Therapeutics's revenue was down 42.6% on a year-over-year basis. During the same period in the prior year, the business earned ($1.12) earnings per share. As a group, sell-side analysts anticipate that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Institutional Trading of Intellia Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. ARK Investment Management LLC raised its holdings in shares of Intellia Therapeutics by 3.8% in the 1st quarter. ARK Investment Management LLC now owns 13,011,015 shares of the company's stock worth $92,508,000 after purchasing an additional 474,629 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Intellia Therapeutics by 5.5% in the first quarter. Vanguard Group Inc. now owns 10,752,031 shares of the company's stock worth $76,447,000 after acquiring an additional 561,978 shares in the last quarter. Regeneron Pharmaceuticals Inc. purchased a new position in shares of Intellia Therapeutics in the fourth quarter worth approximately $43,177,000. Geode Capital Management LLC increased its position in shares of Intellia Therapeutics by 2.0% in the fourth quarter. Geode Capital Management LLC now owns 2,389,240 shares of the company's stock worth $27,865,000 after acquiring an additional 45,930 shares in the last quarter. Finally, Two Sigma Advisers LP increased its position in shares of Intellia Therapeutics by 94.5% in the fourth quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company's stock worth $23,300,000 after acquiring an additional 970,700 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.